GlassScriptPhysician profile
Kelly Doyle Dewitt
NPI 1184668741
$5,862.91
in general payments reported to CMS, 2019-2025
68 companies · $1,691 in 2025
The $1,691 reported for 2025 was more than what 88% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $34.48 · 2021: $95.27 · 2022: $683 · 2023: $1,597 · 2024: $1,503 · 2025: $1,691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,791.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,791.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $767.76 | 2019-2025 | |
| Incyte Corporation | $358.31 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Bayer Healthcare Pharmaceuticals INC. | $255.67 | 2019-2025 | |
| Daiichi Sankyo INC. | $254.77 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Genzyme Corporation | $245.85 | 2019-2025 | |
| Janssen Biotech, INC. | $208.61 | 2022-2025 | Tecvayli, Darzalex, Talvey |
| Merck Sharp & Dohme LLC | $204.69 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $183.61 | 2022-2025 | Ninlaro, Fruzaqla |
| Lilly USA, LLC | $181.69 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Astrazeneca Pharmaceuticals LP | $180.74 | 2022-2025 | Enhertu |
| Pfizer INC. | $143.28 | 2021-2025 | |
| Eisai INC. | $135.55 | 2023-2025 | |
| Icotec Medical INC. | $123.23 | 2024 | Icotec Blackarmor Spine System |
| Puma Biotechnology, INC. | $110.88 | 2022-2025 | |
| Beigene USA, INC. | $109.36 | 2023-2025 | Brukinsa |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Dewitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.